N-acetylcysteine in Bulimia Nervosa
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01131572|
Recruitment Status : Terminated
First Posted : May 27, 2010
Last Update Posted : May 10, 2013
|Condition or disease||Intervention/treatment||Phase|
|NAC||Drug: N-acetylcysteine NAC||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||March 2012|
|Actual Study Completion Date :||March 2012|
open label treatment. Each subject receives N-acetylcysteine.
Drug: N-acetylcysteine NAC
N-acetylcysteine in the treatment of Bulimia Nervosa
- Binge-purge episodes [ Time Frame: per week ]The primary outcome measure will be the weekly frequency of binge-purge episodes. A binge-purge eating episode will be defined using DSM-IV-TR criteria, and accessed via clinical interview and review of subject take-home diaries at each study visit.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01131572
|United States, Ohio|
|Lindner Center of HOPE|
|Mason, Ohio, United States, 45040|